SONOMA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1589 USD | -0.75% |
|
-0.06% | -11.92% |
Valuation
| Fiscal Period: Marzo | 2019 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 11.26 | 4.539 | 2.48 | - | - |
| Enterprise Value (EV) 1 | 11.26 | 4.539 | 2.48 | 2.48 | 2.48 |
| P/E ratio | -0.66 x | -0.64 x | -0.18 x | -0.35 x | -1.22 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 0.59 x | - | 0.17 x | 0.14 x | 0.11 x |
| EV / Revenue | 0.59 x | - | 0.17 x | 0.14 x | 0.11 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,330 | 4,649 | 15,607 | - | - |
| Reference price 2 | 8.461 | 0.9763 | 0.1589 | 0.1589 | 0.1589 |
| Announcement Date | 7/1/19 | 6/21/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2019 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 18.97 | - | 14.7 | 17.9 | 22.1 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -11.26 | - | -4.61 | -3.36 | -1.3 |
| Operating Margin | -59.35% | - | -31.36% | -18.77% | -5.88% |
| Earnings before Tax (EBT) 1 | -11.34 | - | -5.08 | -3.52 | -1.46 |
| Net income 1 | -11.8 | -5.151 | -5.08 | -3.52 | -1.46 |
| Net margin | -62.19% | - | -34.56% | -19.66% | -6.61% |
| EPS 2 | -12.77 | -1.520 | -0.8900 | -0.4500 | -0.1300 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/1/19 | 6/21/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 2.731 | 3.138 | 3.98 | 4.2 | 4.25 | 4.6 | 4.86 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -1.208 | -0.844 | -1.02 | -0.92 | -0.94 | -0.85 | -0.65 |
| Operating Margin | - | -44.23% | -26.9% | -25.63% | -21.9% | -22.12% | -18.48% | -13.37% |
| Earnings before Tax (EBT) 1 | - | -1.298 | -0.923 | -1.11 | -0.96 | -0.98 | -0.89 | -0.69 |
| Net income 1 | -1.418 | -1.484 | -0.866 | -1.11 | -0.96 | -0.98 | -0.89 | -0.69 |
| Net margin | - | -54.34% | -27.6% | -27.89% | -22.86% | -23.06% | -19.35% | -14.2% |
| EPS 2 | -0.2900 | -0.2900 | -0.0800 | -0.1700 | -0.1400 | -0.1300 | -0.1100 | -0.0800 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/10/23 | 11/13/23 | 2/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | 0.1 | - | - | - | - |
| Capex / Sales | 0.53% | - | - | - | - |
| Announcement Date | 7/1/19 | 6/21/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1589
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.92% | 2.48M | |
| +34.00% | 704B | |
| +26.67% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +15.08% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
- Stock Market
- Equities
- SNOA Stock
- Financials Sonoma Pharmaceuticals, Inc.
